Top

Gepubliceerd in:

2009 | OriginalPaper | Hoofdstuk

10 Cholestatische leverziekten

Auteurs : Prof.dr. U. Beuers, Dr. E.A.J. Rauws, Dr. P.C.J. ter Borg, Dr. H.R. van Buuren, Dr. G. Koek

Uitgeverij: Bohn Stafleu van Loghum

Samenvatting

In dit hoofdstuk worden primaire scleroserende cholangitis, primaire biliaire cirrose en leversarcoïdose behandeld, evenals overige cholestatische leverziekten waarbij het waarschijnlijk geacht wordt dat auto-immuniteit een rol speelt.

vorige hoofdstuk 9 Virale hepatitis

volgende hoofdstuk 11 Auto-immuunhepatitis en overlapsyndromen

EASL Clinical Practice Guidelines:Management of cholestatic liver diseases. J Hepatol 2009;51:237–267.

LaRusso NF, Shneider BL, Black D, et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology 2006;44(3):746–764.PubMedCrossRef

Karlsen TH,Schrumpf E,Boberg KM.Genetic epidemiology of primary sclerosing cholangitis. World J Gastroenterol 2007;13(41):5421–5431.PubMedCentralPubMedCrossRef

O’Mahony CA, Vierling JM. Etiopathogenesis of primary sclerosing cholangitis. Semin Liver Dis 2006; 26(1):3–21.PubMedCrossRef

Adams DH,Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease.Nat Rev Immunol 2006;6(3):244–251.PubMedCrossRef

Terjung B,Bogsch F,Klein R, et al. Diagnostic accuracy of atypical p-ANCA in auto-immune hepatitis using ROC- and multivariate regression analysis. Eur J Med Res 2004;9(9):439–448.PubMed

Lazaridis KN, Gores GJ. Primary sclerosing cholangitis and cholangiocarcinoma. Semin Liver Dis 2006;26(1): 42–51.PubMedCrossRef

Yachimski P, Pratt DS. Cholangiocarcinoma: natural history, treatment, and strategies for surveillance in high-risk patients. J Clin Gastroenterol 2008;42(2):178–190.PubMedCrossRef

Said K, Glaumann H, Bergquist A. Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol 2008;48(4):598–605.PubMedCrossRef

10.

Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36(3):321–327.PubMedCrossRef

11.

Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis.Gastrointest Endosc 2002;56(1):48–54.PubMedCrossRef

12.

Beuers U, Rust C. Overlap syndromes. Semin Liver Dis 2005;25(3):311–320.PubMedCrossRef

13.

Gregorio GV, Portmann B, Karani J, et al. Auto-immune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33(3):544–553.PubMedCrossRef

14.

Buuren HR van,Vleggaar FP, Erkelens WG, et al. Autoimmune pancreatocholangitis: a series of ten patients. Scand J Gastroenterol Suppl 2006(243):70–78.PubMedCrossRef

15.

Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008;134(3):706–715.PubMedCrossRef

16.

Beuers U, Spengler U, Kruis W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992;16(3):707–714.PubMedCrossRef

17.

Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997;336(10): 691–695.PubMedCrossRef

18.

Mitchell SA, Bansi DS,Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of highdose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121(4):900–907.PubMedCrossRef

19.

Olsson R, Boberg KM, De Muckadell OS, et al. Highdose ursodeoxycholic acid in primary sclerosing cholangitis:a 5-year multicenter, randomized, controlled study.Gastroenterology 2005;129(5):1464–1472.PubMedCrossRef

20.

Cullen SN, Rust C, Fleming K, Edwards C, Beuers U, Chapman R. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 2008;48:792–800.PubMedCrossRef

21.

Lindor KD, Kowdley KV, Luketic VAC, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50 (epub ahead of print).

22.

Beuers U. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nature Clinical Practice 2006;3(6):318–328.PubMed

23.

Brandsaeter B, Isoniemi H, Broome U, et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol 2004;40(5):815–822.PubMedCrossRef

24.

Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124(4):889–893.PubMedCrossRef

25.

Milligen de Wit AW van, Rauws EA, Bracht J van, et al. Lack of complications following short-term stent therapy for extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc 1997;46(4): 344–347.PubMedCrossRef

26.

Stiehl A, Rudolph G, Sauer P, et al. Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study. J Hepatol 1997;26(3):560–566.PubMedCrossRef

27.

Baluyut AR, Sherman S, Lehman GA, Hoen H, Chalasani N. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc 2001;53(3):308–312.PubMedCrossRef

28.

Welsh FK, Wigmore SJ. Roux-en-Y Choledochojejunostomy is the method of choice for biliary reconstruction in liver transplantation for primary sclerosing cholangitis. Transplantation 2004;77(4):602–604.PubMedCrossRef

29.

Tischendorf JJ, Geier A, Trautwein C. Current diagnosis and management of primary sclerosing cholangitis. Liver Transpl 2008;14(6):735–746.PubMedCrossRef

30.

Metcalf JV, Bhopal RS, Gray J, Howel D, James OF. Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle upon Tyne, England. Int J Epidemiol 1997;26(4):830–836.PubMedCrossRef

31.

Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making.Hepatology 1989;10(1):1–7.PubMedCrossRef

32.

Vleggaar FP, Buuren HR van, Zondervan PE, Kate FJ ten, Hop WC. Jaundice in non-cirrhotic primary biliary cirrhosis: the premature ductopenic variant. Gut 2001;49(2):276–281.PubMedCentralPubMedCrossRef

33.

Jones DE, Newton JL. An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. Aliment Pharmacol Ther 2007;25(4):471–476.PubMedCrossRef

34.

Wolfhagen FH, Engelkens HJ, Buuren HR van. [De pathofysiologie en behandeling van cholestatische jeuk]. Ned Tijdschr Geneeskd 1998;142(13):688–692.PubMed

35.

Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113(3): 884–890.PubMedCrossRef

36.

Corpechot C, Carrat F, Bahr A, Chretien Y,Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005;128(2):297–303.PubMedCrossRef

37.

Jorgensen R, Angulo P, Dickson ER, Lindor KD. Results of long-term ursodiol treatment for patients with primary biliary cirrhosis. Am J Gastroenterol 2002;97(10):2647–2650.PubMedCrossRef

38.

Borg PC ter, Schalm SW, Hansen BE, Buuren HR van, Dutch PBC Study Group. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-year cohort study involving 297 patients. Am J Gastroenterol 2006;101(9):2044–2050.PubMedCrossRef

39.

Pietinalho A, Hiraga Y, Hosoda Y, Lofroos AB, Yamaguchi M, Selroos O. The frequency of sarcoidosis in Finland and Hokkaido, Japan. A comparative epidemiological study. Sarcoidosis 1995;12:61–67.PubMed

40.

Thomeer M, Demedts M, Vandeurzen K. Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders.Acta Clin Belg 2001;56:163–172.PubMedCrossRef

41.

Farman J, Ramirez G, Rybak B, Lebwohl O, Semrad C, Rotterdam H. Gastric sarcoidosis. Abdominal Imaging 1997;22:248–252.PubMedCrossRef

42.

Klatskin G. Hepatic granulomata: problems in interpretation. Mount Sinai Journal of Medicine, New York 1977;44:798–812.PubMed

43.

Lehmuskallio E, Hannuksela M, Halme H. The liver in sarcoidosis. Acta Medica Scandinavica 1977;202:289–293.PubMedCrossRef

44.

Lynch JP 3^rd, Sharma OP, Baughman RP. Extrapulmonary sarcoidosis. Seminars in Respiratory Infections 1998;13:229–254.PubMed

45.

Vatti R, Sharma OP. Course of asymptomatic liver involvement in sarcoidosis: role of therapy in selected cases. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases. Official journal of WASOG (World Association of Sarcoidosis and Other Granulomatous Disorders) 1997; 14:73–76.

46.

Devaney K, Goodman ZD, Epstein MS, Zimmerman HJ, Ishak KG. Hepatic sarcoidosis. Clinicopathologic features in 100 patients. Am J Surg Pathol 1993;17:1272–1280.PubMedCrossRef

47.

Hercules HD, Bethlem NM. Value of liver biopsy in sarcoidosis. Archives of Pathology and Laboratory Medicine 1984;108:831–834.PubMed

48.

Irani SK, Dobbins WO 3^rd. Hepatic granulomas: review of 73 patients from one hospital and survey of the literature. Journal of Clinical Gastroenterology 1979;1:131–143.PubMed

49.

Chamuleau RA, Sprangers RL, Alberts C, Schipper ME. Sarcoidosis and chronic intrahepatic cholestasis. Netherlands Journal of Medicine 1985;28:470–476.

50.

Gaya DR, Thorburn D, Oien KA, Morris AJ, Stanley AJ. Hepatic granulomas: a 10 year single centre experience. Journal of Clinical Pathology 2003;56:850–853.PubMedCentralPubMedCrossRef

51.

Moller DR. Treatment of sarcoidosis – from a basic science point of view. J Intern Med 2003;253:31–40.PubMedCrossRef

52.

James DG, Sherlock S. Sarcoidosis of the liver. Sarcoidosis 1994;11:2–6.PubMed

53.

Israel HL, Margolis ML, Rose LJ. Hepatic granulomatosis and sarcoidosis. Further observations. Dig Dis Sci 1984;29:353–356.PubMedCrossRef

54.

Maddrey WC, Iber FL, Thacker CK, Basu-Mallick KC, Basu AK. Sarcoidosis: clinical manifestations and diagnosis. Indian J Med Res 1968;56:1045–1053.PubMed

55.

Warshauer DM, Molina PL, Hamman SM, Koehler RE, Paulson EK, Bechtold RE, Perlmutter ML, Hiken JN, Francis IR, Cooper CJ, et al. Nodular sarcoidosis of the liver and spleen: analysis of 32 cases. Radiology 1995; 195:757–762.PubMedCrossRef

56.

Costabel U, Hunninghake GW. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur Respir J 1999;14: 735–737.PubMedCrossRef

57.

Hunninghake GW,Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, Eklund A, Kitaichi M, Lynch J, Rizzato G, Rose C, Selroos O, Semenzato G, Sharma OP. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:149–173.PubMed

58.

Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999;160:736–755.CrossRef

59.

Murphy JR, Sjogren MH, Kikendall JW, Peura DA, Goodman Z. Small bile duct abnormalities in sarcoidosis. Journal of Clinical Gastroenterology 1990;12: 555–561.PubMedCrossRef

60.

Baratta L, Cascino A, Delfino M, Giorgino F, Vitolo D, Lagana B, Urani C, Rossi Fanelli F. Ursodeoxycholic acid treatment in abdominal sarcoidosis. Digestive diseases and sciences 2000;45:1559–1562.PubMedCrossRef

61.

Becheur H, Dall’osto H, Chatellier G, Charton Bain MC, Aubertin JM, Attar A, Bloch F, Petite JP. Effect of ursodeoxycholic acid on chronic intrahepatic cholestasis due to sarcoidosis. Digestive Diseases and Sciences 1997;42:789–791.PubMedCrossRef

62.

Ulbricht KU, Stoll M, Bierwirth J, Witte T, Schmidt RE. Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis. Arthritis and Rheumatism 2003;48:3542–3543.PubMedCrossRef

63.

Casavilla FA, Gordon R, Wright HI, Gavaler JS, Starzl TE, Van Thiel DH. Clinical course after liver transplantation in patients with sarcoidosis. Annals of Internal Medicine 1993;118:865–866.PubMedCentralPubMedCrossRef

64.

Fidler HM, Hadziyannis SJ, Dhillon AP, Sherlock S, Burroughs AK. Recurrent hepatic sarcoidosis following liver transplantation. Transplantation Proceedings 1997;29:2509–2510.PubMedCrossRef

65.

Hunt J, Gordon FD, Jenkins RL, Lewis WD, Khettry U. Sarcoidosis with selective involvement of a second liver allograft: report of a case and review of the literature. Modern Pathology. An official journal of the United States and Canadian Academy of Pathology, Inc 1999; 12:325–328.

Titel: 10 Cholestatische leverziekten
Auteurs: Prof.dr. U. Beuers
Dr. E.A.J. Rauws
Dr. P.C.J. ter Borg
Dr. H.R. van Buuren
Dr. G. Koek
Uitgeverij: Bohn Stafleu van Loghum
Boek: Leverziekten
Print ISBN: 978-90-313-7436-6

Elektronisch ISBN: 978-90-313-7437-3

Copyright: 2009
DOI: https://doi.org/10.1007/978-90-313-7437-3_10

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen